Atlas Trials

Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

Clinical trial NCT07439055 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07439055
Sponsor
Chulalongkorn University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Hemophilia A Patient
Start date
2025-06-01
Primary completion
2026-03-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.